Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis

Guang-Li Zhu1,2 | Kai-Bin Yang2 | Si-Qi Tang2 | Liang Peng1

1Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, Guangzhou, P. R. China
2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China

Correspondence
Liang Peng, Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University; Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, Guangzhou 510060, P. R. China.
Email: pengliang5@mail.sysu.edu.cn

Abstract
Progression-free survival (PFS) has been used as a surrogate endpoint for overall survival (OS) in lung cancer trials. The pattern of response to immune-checkpoint inhibitors (ICIs) differs from that to conventional chemotherapy, so immune-related response evaluation criteria were proposed. This study aims at determining which PFS measure, PFS assessed per immune-related response evaluation criteria (iPFS), or conventional criteria (cPFS), is the better surrogate endpoint for OS in trials of ICIs in lung cancer. We selected clinical trials in lung cancer that administered ICIs to at least one arm and reported both median OS and median PFS from PubMed, Embase, and The Cochrane Library. We compared the correlation between treatment effect (hazard ratio) on OS and cPFS or iPFS and the correlation between median OS and median cPFS or iPFS using weighted linear regression at trial level. We analyzed 78 ICI arms (13,438 patients) from 54 studies, including 66 arms with cPFS, seven arms with iPFS, and five arms with both kinds of PFS. We demonstrated an excellent correlation between treatment effect (hazard ratio) on OS and iPFS ($R_{WLS}^2 = 0.91$), while the correlation was moderate for cPFS ($R_{WLS}^2 = 0.38$). Similarly, the correlation between median OS and median cPFS or iPFS using weighted linear regression at trial level. We analyzed 78 ICI arms (13,438 patients) from 54 studies, including 66 arms with cPFS, seven arms with iPFS, and five arms with both kinds of PFS. We demonstrated an excellent correlation between treatment effect (hazard ratio) on OS and iPFS ($R_{WLS}^2 = 0.91$), while the correlation was moderate for cPFS ($R_{WLS}^2 = 0.38$). Similarly, the correlation between median OS and median cPFS or iPFS using weighted linear regression at trial level.

KEYWORDS
immune-checkpoint inhibitors, lung cancer, progression-free survival, surrogate endpoints
1 | INTRODUCTION

Lung cancer ranked first worldwide in both incidence and mortality among all malignancies in 2018. For advanced or recurrent lung cancer, the prognosis is still poor. Cytotoxic drugs have limited effect on advanced or recurrent lung cancer. Over the past few years, immune-checkpoint inhibitors (ICIs), including anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have shown favorable efficacy in both advanced non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (SCLC). More trials investigating ICIs in advanced lung cancer are ongoing.

Overall survival (OS) is the gold standard in the evaluation of efficacy in oncology clinical trials. Although the measurement of OS is simple and reliable, the treatment effect on OS can be diluted by cross-over, successive lines of therapy after progression, and non-cancer-related death, therefore usually larger samples are required in order to detect OS differences across treatment arms in clinical trials. Moreover, evaluation of OS usually requires a long time to follow-up. Thus, under the circumstances of rapid development and urgent demand of novel immunotherapies, appropriate surrogate endpoints such as progression-free survival (PFS) are expected to be applied to assessing the clinical benefit over a shorter period, thereby accelerating the development and introduction of new regimens and drugs into real-world clinical practice. PFS has been used as a surrogate endpoint in the trials in lung cancer at both trial level and individual-patient-data level.

Assessment of treatment effect on PFS is based on the determination of response or progression. However, criteria for evaluation of response vary greatly. The World Health Organization (WHO) criteria published in 1979 assess the patient as showing complete response, partial response, stable disease, or progressive disease according to two dimensions, namely, changes in size and number of lesions. The Response Evaluation Criteria in Solid Tumors (RECIST) specifications, published in 2000, presented measures instead along a single dimension and refined some other details. In 2009, Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) further updated the assessment of tumor burden and lymph nodes, and the confirmation of response based on new clinical evidence. These are the most frequently used conventional response evaluation criteria in chemotherapy trials. However, the pattern of response to immunotherapy differs from that of response to conventional chemotherapy. Immunotherapy usually takes a longer lag time for a suitable response. Meanwhile, some patients receiving ICIs might experience enlargement of preexisting lesions or presence of new lesions during the initial phase of treatment due to transient immune cell infiltration and accumulation of cancer cell debris, which is known as pseudoprogression. The response rate of immunotherapies will be underestimated if assessed per conventional criteria. Thus, the new response evaluation criteria designed for immunotherapies are warranted to capture actual progression and identify real efficacy in patients receiving ICIs. In 2009, the immune-related response criteria (irRC) was proposed based on the WHO criteria. The key point of irRC is ‘wait-and-see’. Considering the phenomena of delayed response and pseudoprogression in ICI therapies, immunotherapy will not cease right after the advent of progression assessed per conventional criteria, and assessment of progressive disease is required to be confirmed with a repeated scan at least 4 weeks later. In 2014 and 2017 respectively, two new immune-related response evaluation criteria, immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) and irRECIST, were published. Although more details have been refined in these new criteria, the key idea of wait-and-see has not changed.

These immune-related response evaluation criteria were designed based on the atypical pattern of response in patients receiving ICIs, but whether they perform better than conventional response evaluation criteria in assessment of efficacy or clinical benefit in trials of ICIs in lung cancer has not previously been validated at trial level. To assess the survival benefit of an intervention based on the treatment effect on surrogate endpoints, there should be a strong and robust correlation between surrogate endpoints and OS. Thus, this systematic review and meta-analysis compares the trial-level correlation between OS and PFS assessed per conventional or immune-related response evaluation criteria to determine which is the better surrogate endpoint for OS in trials of ICIs in lung cancer.

2 | MATERIAL AND METHODS

The protocol for this systematic review and meta-analysis was registered at the PROSPERO International Prospective Register of Systematic Reviews (registration number: CRD42020199492 [Centre for Reviews and Dissemination, University of York, York, United Kingdom]). The methods and reporting of this systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

2.1 | Eligibility criteria

The eligible studies met the following PICOS (participants, interventions, comparisons, outcomes, and study design)
criteria. (1) The participants were patients with primary lung cancer (including NSCLC and SCLC). (2) At least one arm of the trial was treated with regimens including ICIs such as the anti-CTLA-4 inhibitors and anti-PD-1/PD-L1 inhibitors. (3) The comparisons were not restricted. (4) At least one arm investigating ICIs of the study reported both median PFS and median OS. (5) The study type was limited to prospective clinical trials. The language was not restricted.

2.2 | Search strategy and study selection

We searched PubMed, EMBASE, and The Cochrane Library for all eligible clinical trials from inception to 4 July 2020. Search terms included ‘lung cancer’, ‘nivolumab’, ‘cemiplimab’, ‘avelumab’, ‘atezolizumab’, ‘durvalumab’, ‘PD-1’, ‘PD-L1’, and ‘CTLA-4’. Duplicate publications were excluded. For multiple publications or results from a single trial in the same patient population, only the latest publication or result was included. Pooled analyses from more than one trial were also excluded. Two investigators (Guang-Li Zhu and Kai-Bin Yang) screened the titles and abstracts for potentially eligible studies and then screened the full text of these studies to select fully eligible studies independently. Conference abstracts providing sufficient information were also included. Disagreements between investigators were resolved by consensus or referring to a third investigator (Liang Peng).

2.3 | Data extraction

Two independent investigators (Guang-Li Zhu and Kai-Bin Yang) extracted the following data from eligible studies: clinical trial registration number, any other name of the trial, phase of clinical trial, type of lung cancer, stage of lung cancer, enrollment period, median follow-up time, number of arms, intervention in each arm, dose of ICIs, intention-to-treat sample size of each arm, hazard ratios (HR) for PFS or OS, median OS, median PFS, and criteria for evaluation of response. Missing information could be retrieved from registers such as clinicaltrial.gov according to clinical trial registration number when available.

Disagreements between the two investigators were resolved by consensus or referring to a third investigator (Liang Peng).

2.4 | Outcome of interest

Clinical outcomes analyzed were OS and PFS. OS was defined as the time from randomization or initiation of treatment until death from any cause. PFS was defined as the time from randomization or initiation of treatment to first progression (locoregional or distant) or death from any cause. According to different response evaluation criteria, the PFS could be denoted as cPFS (assessed per conventional response evaluation criteria) or iPFS (assessed per immune-related response evaluation criteria). For each comparison between an ICI arm and another arm, the HR for OS and the HR for cPFS/iPFS were paired. For each arm investigating ICIs, the median OS and median cPFS/iPFS were paired.

2.5 | Statistical analysis

We performed the analysis at the trial or arm level, without individual patient-level data incorporated. Analysis of trial-level correlation between OS and PFS included only the treatment arms investigating ICIs. We applied the weighted linear regression model to quantify the trial-level correlation between the HR of OS and iPFS/cPFS after logarithmic transformation. Missing HRs of OS and iPFS/cPFS were not imputed. Points were weighted by the intention-to-treat sample size. We also calculated the surrogate threshold effect (STE) for both criteria. STE is the minimal treatment effect on the surrogate endpoint explaining a nonzero effect on the true endpoint, which is yielded by intersecting the upper prediction limit curve and the horizontal line where HR_{OS} = 1 (zero effect). Besides, we also applied the linear regression model weighted by sample size to quantify the trial-level correlation between median OS and median iPFS/cPFS. Furthermore, considering the heterogeneity across different phases of trials and different types of lung cancer, ICI and treatment modalities, we performed several sensitivity analyses that stratified the treatment arms by (1) type of lung cancer (SCLC, NSCLC); (2) phase of clinical trials (phase 1 or 1b trials, phase 2 trials); (3) types of ICI (anti-PD1 or PD-L1, anti-CTLA-4, dual ICI); (4) treatment modalities (ICI alone, ICI + chemotherapy). Only the groups including more than three studies will be included in the stratified analysis. We calculated the weighted coefficient of determination of linear regression (R_{WLS}^2) to quantify the variation of OS explained by the iPFS/cPFS. We assessed the strength of correlation as excellent (R_{WLS}^2 > 0.90), very good (0.75 < R_{WLS}^2 ≤ 0.90), good (0.50 < R_{WLS}^2 ≤ 0.75), moderate (0.25 < R_{WLS}^2 ≤ 0.50), and poor (R_{WLS}^2 ≤ 0.25). Meanwhile, to ensure the robustness of regression and correlation, we applied leave-one-out cross validation to each weighted linear regression model and calculated the R^2 of leave-one-out cross validation (R_{LOO}^2), root mean squared error, and mean absolute error. Finally, the possibility of publication bias was assessed by visual estimate.
of the funnel plot and Egger's test when at least 10 trials were pooled.

All statistical analyses were performed by R software (version 3.6.2).

3 | RESULTS

3.1 | Selection of studies

After excluding duplicates, we initially identified a total of 1521 records from PubMed, EMBASE, and The Cochrane Library. After screening the abstracts and titles, we excluded 1241 records, of which 1090 were not results of clinical trials, 30 did not report data on lung cancer, nine did not investigate ICIs, and 112 were not the latest of multiple publications all based upon the same trials. We conducted full-text review for the remaining 280 potentially eligible studies, among which 226 did not report both median OS and median PFS. Finally, a total of 54 eligible studies17–68 were included for analysis (Figure 1).

3.2 | Study characteristics

An overview of the included studies is presented in Table S1. A total of 78 arms from all 54 studies, including 13,438 patients, investigated regimens containing ICIs, among which four arms were evaluated per both irRC and modified WHO criteria, one arm was evaluated per irRC and RECIST v1.1, six arms were evaluated per irRC, and one arm was evaluated per irRECIST. For the remaining 66 arms, two arms were evaluated per modified WHO criteria, and 64 arms per RECIST v1.1.

3.3 | Trial-level correlation between treatment effect (HR) on OS and PFS assessed per different response evaluation criteria

Table 12,17–68 demonstrates the extracted information about OS and PFS. From the 54 included studies, we retrieved 36 pairs of HR for OS and PFS (30 per conventional response evaluation criteria only, two per irRC only, and four per both criteria).

Table 2 presents the result of weighted linear regression between HR of median iPFS and median OS was lower than $R_{\text{WLS}}^2$, it still indicates a very good relationship. And the $R_{\text{LOO}}^2$ and $R_{\text{WLS}}^2$ are the same for the weighted linear regression between HR of median cPFS and median OS, indicating a robust but moderate correlation. Given the limited availability of HR of iPFS, sensitivity analysis was not performed. The STEs for the HR of iPFS and cPFS were 0.75 and 1.21, respectively, which are the maximal HR for observed iPFS and cPFS needed to report possibly significant treatment effect on OS.

3.4 | Trial-level correlation between median OS and median iPFS/cPFS

For the ICI arms evaluated by conventional criteria, the mean and standard deviation of median OS and median cPFS were 12.98 ± 5.33 months and 4.30 ± 2.39 months, respectively, whereas the mean and standard deviation of median OS and median iPFS were 10.14 ± 3.44 months and 4.93 ± 1.75 months for the ICI arms evaluated by immune-related criteria.

Table 3 demonstrates the result of weighted linear regression between median OS and median iPFS/cPFS for all arms and different subgroups. The correlation between median OS and median iPFS was very good ($R_{\text{WLS}}^2 = 0.88$; Figure 3A), while the correlation between median OS and median cPFS was weaker ($R_{\text{WLS}}^2 = 0.55$) but still good (Figure 3B). Outliers are data points with studentized residual outside the ±2 range. There are two notable outliers: studies reported by Peters et al.35 and Goldman et al.52. After we excluded these two studies, there was a slight change in the slope and intercept of the weighted linear regression model but an obvious increase in $R_{\text{WLS}}^2$ to 0.62 (Figure 3C). In the leave-one-out cross validation, the correlation between median OS and median cPFS ($R_{\text{LOO}}^2 = 0.40$), or even the correlation after excluding the two outlier studies ($R_{\text{LOO}}^2 = 0.62$), was still weaker than the correlation between median OS and median iPFS ($R_{\text{LOO}}^2 = 0.81$).

3.5 | Sensitivity analyses

We first performed sensitivity analysis according to the type of lung cancer. For arms investigating SCLC, the median iPFS ($R_{\text{WLS}}^2 = 0.86$) showed a better correlation with median OS than did median cPFS ($R_{\text{WLS}}^2 = 0.67$). Similarly, for arms investigating NSCLC, the median iPFS also showed a stronger correlation with median OS ($R_{\text{WLS}}^2 = 0.96$) than did median cPFS ($R_{\text{WLS}}^2 = 0.51$). Excluding the studies by Peters et al.35 and Goldman et al.52 improved the correlation between median OS and
median cPFS in NSCLC ($R_{WLS}^2 = 0.59$), but it was still much weaker than the correlation between median OS and median iPFS. Leave-one-out cross validation also confirmed this conclusion. $R_{LOO}^2$ improved from 0.27 to 0.56 after removal of the studies by Peters et al. \cite{35} and Goldman et al. \cite{52} indicating an increase in robustness of correlation between median OS and median cPFS, but still did not match the excellent correlation between median OS and median iPFS ($R_{WLS}^2 = 0.93$).

Besides, we also performed sensitivity analysis according to the phase of clinical trials. In the trials assessed per conventional criteria, phase 3 trials (44.7%) predominated, followed by phase 2 trials (23.4%) and phase 1 or 1b trials (23.4%), whereas in the trials assessed per immune-related criteria, phase 2 trials (58.3%) predominated, followed by phase 1 trials (41.7%). For arms from phase 1 or phase 1b trials, the median iPFS showed a much stronger correlation with median OS ($R_{WLS}^2 = 0.92$) than did the median cPFS ($R_{WLS}^2 = 0.51$). After removal of the outlier study by Goldman et al. \cite{52} the $R^2$ of weighted linear regression between cPFS and OS ($R_{WLS}^2 = 0.76$) increased, and the $R_{LOO}^2$ also improved significantly to 0.66 in leave-one-out validation. Similarly for arms from phase 2 trials, the median iPFS still showed a better correlation with median OS ($R_{WLS}^2 = 0.86$) than did median cPFS ($R_{WLS}^2 = 0.28$). And the removal of the outlier study by Peters et al. \cite{35} mildly improved the $R^2$ of weighted linear regression to $R_{WLS}^2 = 0.41$ and of leave-one-out cross validation to $R_{LOO}^2 = 0.39$.

Finally, we performed sensitivity analysis based on the types of ICI and treatment modalities, respectively. Regarding the types of ICI, concerning that only 1 trial used anti-PD-L1 antibody among the trials assessed per immune-related criteria, we combined anti-PD1 and anti-PD-L1 antibody as one group. The correlation between median OS and median iPFS were very good and excellent.

---

**FIGURE 1** Flowchart of the study selection process
| Trials                                      | Regime                | Response evaluation criteria | Sample size | Median OS (months) | Median PFS (months) | Hazard ratio of overall survival | Hazard ratio of progression-free survival |
|--------------------------------------------|-----------------------|-----------------------------|-------------|--------------------|---------------------|----------------------------------|------------------------------------------|
| Gadgeel et al. (2020)                      | Pem + chemo           | RECIST v1.1                 | 410         | 22.0 (19.5–25.2)   | 9.0 (8.1–9.9)       | 0.56 (0.45–0.70)                 | 0.48 (0.40–0.58)                         |
| Mok et al. (2019)                          | Pem                   | RECIST v1.1                 | 637         | 20.0 (15.4–24.9)   | 7.1 (5.9–9)         | NA                               | NA                                       |
| Ott et al. (2017)                          | Pem                   | RECIST v1.1                 | 24          | 9.7 (4.1-NA)       | 1.9 (1.7–5.9)       | NA                               | NA                                       |
| Nishio et al. (2019)                       | Pem                   | RECIST v1.1                 | 38          | 19.2 (8–26.7)      | 3.9 (2–6.2)         | NA                               | NA                                       |
| Gubens et al. (2019)                       | Pem + Ipi             | RECIST v1.1                 | 51          | 10.9 (6.1–23.7)    | 4.1 (1.4–5.8)       | NA                               | NA                                       |
| Herbst et al. (2016)                       | Pem                   | RECIST v1.1                 | 344         | 10.4 (9.4–11.9)    | 3.9 (3.1–4.1)       | 0.71 (0.58–0.88)                 | 0.88 (0.74–1.05)                         |
| Leighl et al. (2019)                       | Pem (treatment naïve) | RECIST v1.1                 | 101         | 22.3 (17.1–31.5)   | 10.3 (8.3–14.7)     | NA                               | NA                                       |
| Reck et al. (2019)                         | Ate + chemo2          | RECIST v1.1                 | 402         | 21.4 (13.8-NA)     | 6.9 (5.7–8.2)       | 0.93 (0.51–1.68)                 | 1.14 (0.73–1.78)                         |
| Horn et al. (2018)                         | Ate + chemo           | RECIST v1.1                 | 201         | 12.3 (10.8–15.9)   | 5.2 (4.4–5.6)       | 0.70 (0.54–0.91)                 | 0.77 (0.62–0.96)                         |
| Barlesi et al. (2018)                      | Ate + chemo           | RECIST v1.1                 | 292         | 18.1 (13-NA)       | 7.6 (6.6–8.5)       | 0.81 (0.64–1.03)                 | 0.60 (0.50–0.72)                         |
| Jotte et al. (2020)                        | Ate + chemo2          | RECIST v1.1                 | 338         | 14.2               | 6.3                 | 0.88 (0.73–1.05)                 | 0.71 (0.60–0.85)                         |
| National Library of Medicine (U.S.). (30 September 2015 – 1 October 2018) | Nivo + Ipi | RECIST v1.1 | 279 | 9.2 (8.2–10.3) | 1.7 (1.5–2.6) | 0.92 (0.75–1.12) | 0.72 (0.60–0.87) |
| National Library of Medicine (U.S.). (28 August 2015 – 17 August 2018) | Nivo | RECIST v1.1 | 280 | 10.4 (9.5–12.1) | 1.9 (1.6–2.6) | 0.84 (0.69–1.02) | 0.67 (0.56–0.81) |
| Peters et al. (2019)                       | Nivo + Ipi            | RECIST v1.1                 | 396         | 17.1 (15.0–20.1)   | 5.1 (4.1–6.3)       | 0.79 (0.65–0.96)                 | 0.82 (0.69–0.97)                         |
| National Library of Medicine (U.S.). (10 December 2015 – 15 September 2017) | Nivo | RECIST v1.1 | 338 | 11.9 (10.4–14.0) | 2.8 (2.4–3.4) | 0.68 (0.52–0.9) | 0.77 (0.62–0.95) |
| Antonia et al. (2016)                      | Nivo                  | RECIST v1.1                 | 98          | 4.4 (3.0–9.3)      | 1.4 (1.4–1.9)       | NA                               | NA                                       |
| Carbone et al. (2017)                      | Nivo                  | RECIST v1.1                 | 271         | 4.2 (3.0–5.6)      | 4.2 (3.1–5.5)       | 1.15 (0.91–1.45)                 | 1.17 (0.95–1.43)                         |
| Horn et al. (2017)                         | Nivo                  | RECIST v1.1                 | 131         | 9.2 (7.1–12.6)     | 3.5 (2.1–5.1)       | NA                               | NA                                       |
| Trials                          | Regime            | Response evaluation criteria | Sample size | Median OS (months) | Median PFS (months) | Hazard ratio of overall survival | Hazard ratio of progression-free survival |
|--------------------------------|-------------------|-------------------------------|-------------|-------------------|---------------------|-------------------------------|------------------------------------------|
| Horn et al. (2017)\(^{33}\)     | Nivo              | RECIST v1.1                   | 287         | 12.2 (9.7–15.1)   | 2.3 (2.2–3.4)       | NA                            | NA                                       |
| Gettinger et al. (2015)\(^{34}\) | Nivo              | RECIST v1.1                   | 129         | 9.9 (7.8–12.4)    | 2.3 (1.8–3.7)       | NA                            | NA                                       |
| Peters et al. (2017)\(^{35}\)   | Ate (no prior chemo) | RECIST v1.1                   | 142         | 23.5 (18.1–NA)    | 5.4 (3.0–6.9)       | NA                            | NA                                       |
|                                | Ate (one prior chemo) | RECIST v1.1                   | 271         | 15.5 (12.3–19.5)  | 2.8 (1.5–3.9)       | NA                            | NA                                       |
|                                | Ate (at least two prior chemo) | RECIST v1.1                   | 254         | 13.2 (10.7–17.5)  | 2.8 (2.7–3.0)       | NA                            | NA                                       |
| Rizvi et al. (2020)\(^{36}\)    | Dur               | RECIST v1.1                   | 374         | 16.3 (12.2–20.8)  | 4.7 (3.1–6.3)       | 0.76 (0.56–1.02)              | 0.87 (0.59–1.29)                         |
|                                | Dur + Tre         | RECIST v1.1                   | 372         | 11.9 (9.0–17.7)   | 3.9 (2.8–5.0)       | 0.85 (0.61–1.17)              | 1.05 (0.72–1.53)                        |
| Planchar et al. (2020)\(^{37}\) | Dur               | RECIST v1.1                   | 62          | 11.7 (8.2–17.4)   | 3.8 (1.9–5.6)       | 0.63 (0.42–0.93)              | 0.71 (0.49–1.04)                         |
|                                | Dur + Tre         | RECIST v1.1                   | 174         | 11.5 (8.7–14.1)   | 3.5 (2.3–4.6)       | 0.8 (0.61–1.05)               | 0.77 (0.59–1.01)                         |
| Wrangle et al. (2018)\(^{38}\)  | Nivo + Alt-803    | RECIST v1.1                   | 23          | 17.4 (9–NA)       | 9.4 (3-NA)          | NA                            | NA                                       |
| Fehrenbacher et al. (2018)\(^{39}\) | Ate               | RECIST v1.1                   | 425         | 13.8 (11.8–15.7)  | 2.8 (2.6–3)         | 0.75 (0.64–0.89)              | 0.93 (0.8–1.08)                          |
|                                | Ate               | RECIST v1.1                   | 613         | 13.3 (11.3–14.9)  | 2.7 (2.4–2.9)       | 0.8 (0.7–0.92)                | 0.96 (0.85–1.08)                         |
| Barlesi et al. (2018)\(^{40}\)  | Ave               | RECIST v1.1                   | 396         | 10.5 (9.2–12.9)   | 2.8 (2.7–3.5)       | 0.9 (0.76–1.07)               | 1.17 (0.98–1.41)                         |
| Kanda et al. (2020)\(^{41}\)    | Nivo + chemo1     | RECIST v1.1                   | 6           | 13.2 (11–55.4)    | 6.3 (0.7–47.8)      | NA                            | NA                                       |
|                                | Nivo + chemo2     | RECIST v1.1                   | 6           | 28.5 (14.6–66.2)  | 11.8 (1.4–65.1)     | NA                            | NA                                       |
|                                | Nivo + chemo4     | RECIST v1.1                   | 6           | 12.5 (9.8–16.9)   | 3.2 (1.9–10.9)      | NA                            | NA                                       |
| Chen et al. (2020)\(^{42}\)     | Nivo              | RECIST v1.1                   | 53          | 11.5 (6.0–13.7)   | 1.4 (1.3–2.6)       | NA                            | NA                                       |
| West et al. (2019)\(^{43}\)     | Ate + chemo       | RECIST v1.1                   | 483         | 18.6 (16.0–21.2)  | 7 (6.7–7.1)         | 0.79 (0.64–0.98)              | 0.64 (0.54–0.77)                         |
| Govindan et al. (2017)\(^{44}\) | Ipi + chemo       | mWHO                         | 388         | 13.4 (11.8–14.8)  | 5.6 (5.4–5.9)       | 0.91 (0.77–1.07)              | 0.87 (0.75–1.01)                         |
| Theelen et al. (2019)\(^{45}\)  | Pem + RT          | RECIST v1.1                   | 38          | 15.9 (7.1–NA)     | 6.6 (4.0–14.6)      | NA                            | NA                                       |
|                                | Pem               | RECIST v1.1                   | 40          | 7.6 (6.0–13.9)    | 1.9 (1.7–6.9)       | 1.52 (0.85–2.72)              | 1.41 (0.85–2.36)                         |
| Owonikoko et al. (2019)\(^{46}\)| Tre/Dur           | RECIST v1.1                   | 8           | 2.6             | 2.1                | NA                            | NA                                       |
|                                | Tre/Dur + SBRT    | RECIST v1.1                   | 7           | 5.7             | 3.3                | 1.50 (0.45–4.99)              | 2.44 (0.75–7.93)                         |
| Paz-Ares et al. (2019)\(^{47}\) | Dur + chemo       | RECIST v1.1                   | 268         | 13 (11.5–14.8)    | 5.1 (4.7–6.2)       | 0.73 (0.59–0.91)              | NA                                       |
| Pujol et al. (2019)\(^{48}\)    | Ate               | RECIST v1.1                   | 49          | 9.5 (3.2–14.4)    | 1.4 (1.2–1.5)       | 0.84 (0.45–1.58)              | 2.26 (1.3–3.93)                          |
| Gettinger et al. (2016)\(^{49}\)| Nivo              | RECIST v1.1                   | 52          | 19.4 (0.5–35.8)   | 3.6 (0.1–28.0)      | NA                            | NA                                       |

(Continues)
| Trials                                                                 | Regime                  | Response evaluation criteria | Sample size | Median OS (months) | Median PFS (months) | Hazard ratio of overall survival | Hazard ratio of progression-free survival |
|----------------------------------------------------------------------|-------------------------|-----------------------------|-------------|--------------------|---------------------|-----------------------------------|-------------------------------------------|
| National Library of Medicine (U.S.) (13 December 2011 – 19 March 2015) | Ipi + chemo             | mWHO                        | 566         | 10.2 (9.6–10.8)    | 4.6 (4.5–5.0)       | 0.96 (0.84–1.10)                  | 0.85 (0.75–0.97)                          |
| National Library of Medicine (U.S.) (6 August 2013 – 19 November 2015) | Ate                     | RECIST v1.1                  | 144         | 12.6 (9.7–16)      | 2.7 (2–4.1)         | 0.69 (0.52–0.92)                  | 0.92 (0.71–1.2)                          |
| Goldman et al. (2019)                                               | Nivo (concurrent)       | RECIST v1.1                  | 22          | 29.3 (9.1–8.5)     | 4.1 (1.3–NA)        | NA                                | NA                                        |
| Bazhenova et al. (2019)                                             | Nivo (delayed)          |                            | 10          | 8.2 (2.2–NA)       | 10.5 (4.9–28.4)     | NA                                | NA                                        |
| Bazhenova et al. (2019)                                             | Nivo + Ipi              | RECIST v1.1                  | 127         | 10.0 (8–12.8)      | 3.8 (2.3–4.2)       | 0.97 (0.71–1.31)                  | 0.84 (0.64–1.09)                          |
| Bazhenova et al. (2019)                                             | Nivo                    |                            | 127         | 11.0 (8.2–13.5)    | 2.9 (1.8–3.9)       | NA                                | NA                                        |
| Cho et al. (2019)                                                   | Mk-1308 + Pem           | RECIST v1.1                  | 40          | 11.0 (5.9–2.0)     | 1.9 (3.9–NA)        | NA                                | NA                                        |
| Paz-Ares et al. (2018)                                              | Pem + chemo             | RECIST v1.1                  | 278         | 15.9 (13.2–NA)     | 6.4 (6.2–8.3)       | 0.64 (0.49–0.85)                  | 0.56 (0.45–0.7)                           |
| Okuma et al. (2018)                                                 | Nivo                    | RECIST v1.1                  | 33          | 3.8 (2.4–16.3)     | 1.5 (1.0–2.7)       | NA                                | NA                                        |
| Lee et al. (2018)                                                   | Nivo                    | RECIST v1.1                  | 100         | 13.9 (10.8–18.5)   | 2.8 (1.4–5.7)       | NA                                | NA                                        |
| Liu et al. (2018)                                                   | Ate + chemo1            | RECIST v1.1                  | 25          | 12.9 (8.8–21.3)    | 7.1 (4.2–8.3)       | NA                                | NA                                        |
| Liu et al. (2018)                                                   | Ate + chemo2            |                            | 25          | 18.9 (9.9–27.4)    | 8.4 (4.7–11)        | NA                                | NA                                        |
| Liu et al. (2018)                                                   | Ate + chemo3            |                            | 26          | 17 (12.7–NA)       | 5.7 (4.4–14.8)      | NA                                | NA                                        |
| Socinski et al. (2019)                                              | Ate                     | RECIST v1.1                  | 152         | 14.8 (12.7–21.3)   | 4.1 (2.8–4.9)       | NA                                | NA                                        |
| Hida et al. (2017)                                                  | Nivo                    | RECIST v1.1                  | 35          | 16.3 (12.4–25.4)   | 4.2 (1.4–7.1)       | NA                                | NA                                        |
| Sequist et al. (2016)                                               | Ate                     | RECIST v1.1                  | 17          | 5.9 (4.3–20.1)     | 1.5 (1.2–2.7)       | NA                                | NA                                        |
| Shaverdian et al. (2017)                                            | Pem + RT                | irRC                        | 42          | 10.7 (6.5–18.9)    | 4.4 (2.1–8.6)       | 0.58 (0.36–0.94)                  | 0.56 (0.34–0.91)                          |
| Shaverdian et al. (2017)                                            | Pem                     |                            | 55          | 5.3 (2.7–7.7)      | 2.1 (1.6–2.3)       | NA                                | NA                                        |
| Shaverdian et al. (2017)                                            | Pem + extracranial RT   |                            | 38          | 11.6 (6.5–20.5)    | 6.3 (2.1–10.4)      | 0.59 (0.36–0.94)                  | 0.50 (0.30–0.84)                          |
| Shaverdian et al. (2017)                                            | Pem                     |                            | 59          | 5.3 (3–8.5)        | 2.0 (1.8–2.1)       | NA                                | NA                                        |
| Lynch et al. (2012)                                                 | Ipi + concurrent chemo  | irRC                        | 70          | 11.0 (8.4–12.8)    | 5.5 (4.2–6.7)       | 0.96 (0.63–1.48)                  | 0.78 (0.53–1.13)                          |
| Lynch et al. (2012)                                                 | Ipi + phased chemo      |                            | 68          | 11.6 (9.3–14.4)    | 5.7 (4.8–7.8)       | 0.75 (0.48–1.18)                  | 0.69 (0.47–1.01)                          |
| Lynch et al. (2012)                                                 | Ipi + concurrent chemo  |                            | 70          | 11.0 (8.4–12.8)    | 4.1 (2.8–5.3)       | 0.96 (0.63–1.48)                  | 0.88 (0.61–1.27)                          |
| Lynch et al. (2012)                                                 | Ipi + phased chemo      |                            | 68          | 11.6 (9.3–14.4)    | 5.1 (4.2–5.7)       | 0.75 (0.48–1.18)                  | 0.69 (0.48–1.00)                          |
ZHU et al.

Trials Regime Response evaluation criteria Sample size Median OS (months) Median PFS (months) Hazard ratio of overall survival Hazard ratio of progression-free survival

Reck et al. (2013)64 Ipi + concurrent chemo irRC 43 9.1 (8.6–11.7) 5.7 (5.2–6.9) 0.95 (0.59–1.54) 0.75 (0.48–1.19)
Ipi + phased chemo mWHO 43 9.1 (8.6–11.7) 3.9 (2.9–5.9) 0.95 (0.59–1.54) 0.93 (0.59–1.48)
Ipi + concurrent chemo irRC 42 12.9 (7.9–16.5) 5.2 (4.1–6.6) 0.75 (0.46–1.23) 0.93 (0.59–1.45)
Ipi + phased chemo irRC 42 17.0 (7.9–24.3) 7.3 (5.5–8.8) NA NA

Arriola et al. (2016)65 Ipi + chemo irRC 53 17.0 (7.9–24.3) 7.3 (5.5–8.8) NA NA

Gadgeel et al. (2017)66 Pem irRC 45 9.2 (6.1–15.2) 4.7 (1.8–6.7) NA NA

Mattes et al. (2019)67 ICI + RT irRECIST 34 12.0 6.1 NA NA

Chiang et al. (2020)68 Ate irRC 17 5.9 (4.3–12.6) 2.9 (1.2–6.1) NA NA
Ate RECIST v1.1 17 5.9 (4.3–12.6) 1.5 (1.2–2.7) NA NA

Abbreviations: Ate, atezolizumab; Ave, avelumab; Chemo, chemotherapy; Dur, durvalumab; ICI, immune-checkpoint inhibitors; Ipi, ipilimumab; NA, not available; Nivo, nivolumab; RT, radiotherapy; Tre, tremelimumab.

TABLE 2 Weighted linear correlation between treatment effect (hazard ratio) on overall survival and progression-free survival

| Correlation between                                                                 | Included arms | Slope | p-value for slope | R^2 of weighted linear regression | Adjusted R^2 of weighted linear regression | R_L^2 of leave-one-out cross validation | Root mean square error | Mean absolute error |
|------------------------------------------------------------------------------------|---------------|-------|-------------------|-----------------------------------|-------------------------------------------|----------------------------------------|------------------------|---------------------|
| Hazard ratio of OS and hazard ratio of cPFS after logarithmic transformation       | All arms      | 0.37  | <0.01             | 0.38                              | 0.36                                      | 0.38                                   | 0.17                   | 0.13                |
| Hazard ratio of OS and hazard ratio of iPFS after logarithmic transformation      | All arms      | 1.25  | <0.01             | 0.91                              | 0.89                                      | 0.77                                   | 0.11                   | 0.09                |

Abbreviations: cPFS, progression-free survival assessed per conventional response evaluation criteria; iPFS, progression-free survival assessed per immune-related response evaluation criteria; OS, overall survival.
in anti-CTLA-4 group ($R_{WLS}^2 = 0.93$) and anti-PD1/anti-PD-L1 group ($R_{WLS}^2 = 0.88$), respectively, while a very good and good correlation were detected between median OS and median cPFS in anti-CTLA-4 group ($R_{WLS}^2 = 0.80$) and anti-PD1/anti-PD-L1 group ($R_{WLS}^2 = 0.57$), respectively. As for the types of treatment modalities, limited by the number of trials, the stratified analysis could not be performed in ICI alone group for iPFS and ICI + radiotherapy group for both iPFS and cPFS. We detected a moderate and very good correlation between OS and cPFS in ICI alone group ($R_{WLS}^2 = 0.46$) and ICI + chemotherapy group ($R_{WLS}^2 = 0.84$), respectively. However, the correlation between OS and iPFS in ICI + chemotherapy ($R_{WLS}^2 = 0.86$) group was stronger. In addition, correlation between median OS and median iPFS ($R_{LOO}^2$ ranging from 0.65 to 0.84) were also more robust than median OS and median cPFS ($R_{LOO}^2$ ranging from 0.28 to 0.79) as demonstrated in the leave-one-out cross validation.

### 3.6 Assessment of publication bias

The funnel plot is highly symmetric, and Egger’s test shows no evidence of publication bias in the arms reporting HR of OS ($p = 0.66$) and PFS ($p = 0.64$) assessed per conventional response evaluation criteria (Figure S1). Fewer than 10 arms reported HR of OS and PFS assessed per immune-related response evaluation criteria, so their publication bias was not evaluated.

### 4 DISCUSSION

The first ICI used to treat advanced NSCLC, nivolumab, was approved in 2015. In 2016, pembrolizumab was approved as a first-line treatment option for metastatic NSCLC. Great breakthroughs by the emerging ICIs in prolonging the survival of patients with advanced lung cancer have elicited a rapidly increased number of trials of ICIs in lung cancer. An appropriate surrogate endpoint for OS to predict clinical benefit at an early phase of trials and accelerate patients’ access to new ICIs is therefore urgently needed. In this study, we aimed at comparing the correlation between OS and PFS assessed per immune-related and conventional response evaluation criteria in lung cancer patients receiving ICIs at trial level.

The trial-level correlation between the HR of OS and cPFS was moderate ($R_{WLS}^2 = 0.36$). The trial-level correlation between OS and cPFS was worse than in previously reported studies, which included only trials of conventional chemotherapy.4–6,8 Similarly, there is a good or very good trial-level correlation between median OS and median cPFS ($R_{WLS}^2$ ranging from 0.51 to 0.80) for all arms and subgroups except phase 2 trials or trials using ICI alone, which only exhibited moderate correlation even after the removal of the outlier studies. However, in the leave-one-out cross validation for all arms and subgroups, we only detected a $R_{LOO}^2$ greater than 0.5 in three subgroups, indicating a moderate power of prediction. The atypical pattern of response and various regimens of ICIs with or without conventional cytotoxic drugs might lower the predictive value of cPFS as a surrogate marker under these less restrictive circumstances. Thus, the above evidence provides only moderate support for considering cPFS as an appropriate surrogate endpoint for OS in trials of ICIs in lung cancer.

Conversely, the trial-level correlation between the HR of OS and iPFS was excellent ($R_{WLS}^2 = 0.91$), which was validated by the leave-one-out cross validation ($R_{LOO}^2 = 0.77$). STE was 0.75 for iPFS, indicating that with an HR of iPFS lower than 0.75 we could predict a statistically significant HR of OS. Moreover, the considerably higher STE of 1.21 for cPFS means that even patients with worse cPFS under immunotherapy than control treatment (PFS HR >1), can derive statistically significant OS benefit with immunotherapy compared to control treatment, indicating the underestimation of the OS benefit of immunotherapy with the cPFS evaluation per conventional criteria. Moreover, we also demonstrated a very good
### Table 3: Weighted linear correlation between overall survival and progression-free survival

| Correlation between | Included arms | Slope of weighted linear regression | p-value for slope | $R^2$ of weighted linear regression | Adjusted $R^2$ of weighted linear regression | $R_L^2$ of leave-one-out cross validation | Root mean square error | Mean absolute error |
|---------------------|---------------|-------------------------------------|-------------------|------------------------------------|---------------------------------------------|------------------------------------------|----------------------|-------------------|
| Overall             | All arms      | 1.61                                | <0.01             | 0.55                               | 0.54                                        | 0.40                                      | 4.17                 | 3.01              |
|                     | All arms excluding studies by Peters et al.\(^{35}\) and Goldman et al.\(^{52}\) | 1.67 | <0.01 | 0.62 | 0.61 | 0.62 | 3.06 | 2.48 |
| **Type of lung cancer** | SCLC          | 1.27                                | <0.01             | 0.67                               | 0.65                                        | 0.45                                      | 2.44                 | 2.01              |
|                     | NSCLC         | 1.53                                | <0.01             | 0.51                               | 0.50                                        | 0.27                                      | 4.51                 | 3.18              |
|                     | NSCLC excluding studies by Peters et al.\(^{35}\) and Goldman et al.\(^{52}\) | 1.61 | <0.01 | 0.59 | 0.58 | 0.56 | 3.15 | 2.56 |
| **Phase of clinical trials** | Phase 1 arms | 1.52                                | <0.01             | 0.51                               | 0.48                                        | 0.27                                      | 5.91                 | 4.04              |
|                     | Phase 1 arms excluding study by Goldman et al.\(^{52}\) | 2.10 | <0.01 | 0.80 | 0.76 | 0.66 | 3.57 | 2.77 |
|                     | Phase 2 arms  | 1.70                                | <0.01             | 0.28                               | 0.25                                        | 0.30                                      | 4.01                 | 3.48              |
|                     | Phase 2 arms excluding study by Peters et al.\(^{35}\) | 1.48 | <0.01 | 0.41 | 0.38 | 0.39 | 3.07 | 2.64 |
| **Type of ICI**     | Anti-PD-1/anti-PD-L1 | 1.59                            | <0.01             | 0.57                               | 0.57                                        | 0.38                                      | 4.46                 | 3.10              |
|                     | Anti-CTLA-4   | 2.78                                | <0.01             | 0.80                               | 0.76                                        | 0.62                                      | 1.11                 | 0.94              |
|                     | Dual ICI      | 2.40                                | <0.01             | 0.81                               | 0.79                                        | 0.28                                      | 3.51                 | 3.05              |
| **Treatment modalities** | ICI alone    | 1.71                                | <0.01             | 0.46                               | 0.44                                        | 0.23                                      | 4.74                 | 3.32              |
|                     | ICI + chemotherapy | 2.73                           | <0.01             | 0.84                               | 0.83                                        | 0.79                                      | 2.43                 | 1.87              |
| **Median OS and median iPFS** | All arms      | 1.84                                | <0.01             | 0.88                               | 0.87                                        | 0.81                                      | 1.43                 | 1.03              |
| **Type of lung cancer** | SCLC arms    | 2.62                                | 0.02              | 0.86                               | 0.81                                        | 0.66                                      | 2.64                 | 2.26              |
|                     | NSCLC arms    | 1.62                                | <0.01             | 0.96                               | 0.95                                        | 0.93                                      | 0.75                 | 0.58              |
| **Phase of clinical trials** | Overall      | 1.61                                | <0.01             | 0.55                               | 0.54                                        | 0.40                                      | 4.17                 | 3.01              |
|                     | All arms      | 1.67                                | <0.01             | 0.62                               | 0.61                                        | 0.62                                      | 3.06                 | 2.48              |
|                     | SCLC          | 1.27                                | <0.01             | 0.67                               | 0.65                                        | 0.45                                      | 2.44                 | 2.01              |
|                     | NSCLC         | 1.53                                | <0.01             | 0.51                               | 0.50                                        | 0.27                                      | 4.51                 | 3.18              |
|                     | NSCLC excluding studies by Peters et al.\(^{35}\) and Goldman et al.\(^{52}\) | 1.61 | <0.01 | 0.59 | 0.58 | 0.56 | 3.15 | 2.56 |
| **Phase of clinical trials** | Phase 1 arms | 1.52                                | <0.01             | 0.51                               | 0.48                                        | 0.27                                      | 5.91                 | 4.04              |
|                     | Phase 1 arms excluding study by Goldman et al.\(^{52}\) | 2.10 | <0.01 | 0.80 | 0.76 | 0.66 | 3.57 | 2.77 |
|                     | Phase 2 arms  | 1.70                                | <0.01             | 0.28                               | 0.25                                        | 0.30                                      | 4.01                 | 3.48              |
|                     | Phase 2 arms excluding study by Peters et al.\(^{35}\) | 1.48 | <0.01 | 0.41 | 0.38 | 0.39 | 3.07 | 2.64 |
| **Type of ICI**     | Anti-PD-1/anti-PD-L1 | 1.59                            | <0.01             | 0.57                               | 0.57                                        | 0.38                                      | 4.46                 | 3.10              |
|                     | Anti-CTLA-4   | 2.78                                | <0.01             | 0.80                               | 0.76                                        | 0.62                                      | 1.11                 | 0.94              |
|                     | Dual ICI      | 2.40                                | <0.01             | 0.81                               | 0.79                                        | 0.28                                      | 3.51                 | 3.05              |
| **Treatment modalities** | ICI alone    | 1.71                                | <0.01             | 0.46                               | 0.44                                        | 0.23                                      | 4.74                 | 3.32              |
|                     | ICI + chemotherapy | 2.73                           | <0.01             | 0.84                               | 0.83                                        | 0.79                                      | 2.43                 | 1.87              |

(Continues)
trial-level correlation between the median OS and median iPFS for all arms ($R_{WLS}^2 = 0.88$). And the $R_{LOO}^2$ was greater than 0.60 for all arms and subgroups in the leave-one-out cross validation. The strong and robust trial-level correlation suggest that median iPFS and HR of iPFS are appropriate surrogate endpoints in trials of ICIs in lung cancer. Another meta-analysis including 14 randomized controlled trials with patients across five types of cancers reported a slightly stronger but still moderate trial-level correlation between iPFS and OS ($R^2 = 0.277$) compared with the correlation between cPFS and OS ($R^2 = 0.260$), which might be associated with heterogeneity of patterns of survival in patients across different types of cancer.69

The importance of adopting a response evaluation criteria adaptive to the unique pattern of response to immune-checkpoint inhibitors has not received adequate attention. Although it has been over 10 years since the
publication of the irRC, RECIST v1.1 is still the most frequently used set of criteria for response evaluation in clinical trials of ICIIs. The immune-related response evaluation criteria were mainly used in early phases of trials, and no result of phase 3 trials evaluated per immune-related response evaluation criteria has yet been identified. There were several reasons why immune-related response criteria were still not widely used in ICI trials. First, prospective randomized trials comparing conventional and immune-related response criteria have yet to be conducted, so there was no confirmatory evidence of the superiority of immune-related response criteria over conventional criteria. In fact, the irRC guidelines did not claim its superiority in the response evaluation in ICI trials, but only recommended prospective validation of the new criteria in the future trials. RECIST criteria are still the most widely used and recognized criteria. Second, implementation of trials with immune-related criteria requires more precautions due to the risk of continuing the treatment after documented progression. Third, the immune-related response criteria were made partly in response to the findings of atypical patterns of response to ICI. However, some oncologists think that the rates of pseudoprogression, which was reported to be less than 10%, is insufficient to lead to a significantly difference in the assessment of PFS, while some oncologists thought that PFS in ICI trials would be better assessed with these new criteria. Thus, this study tries to provide an insight into the importance of immune-related response evaluation criteria in immune-checkpoint inhibitor trials even with limited availability of studies assessed per immune-related response evaluation criteria.

The strength of the evidence of this study was mainly restricted by the limited availability of studies assessed per immune-related response evaluation criteria. The gold standard of surrogate endpoint analysis is the correlation between HR on cPFS or iPFS and HR on OS. However, the lack of phase 3 trials results in a lack of direct comparison of correlation for both types of PFS, which leads to insufficient data on HR. And further analysis, including sensitivity analysis, could not be performed for the correlation between the HR of OS and iPFS. In this study, to further validate the superiority of immune-related response evaluation criteria over conventional criteria, we additionally analyzed the correlation between medians of cPFS or iPFS and medians of OS to make more confirmatory conclusions. Besides, another concern with the lack of Phase III trials with iPFS in this analysis is that the correlation between OS and PFS could be confounded by trial phase. In this study, the lower correlation and poorer prediction power of cPFS could be due to the broader and more heterogeneous patients enrolled in phase 3 trials, while phase 1 and 2 trials are usually more stringent. However, the strong correlation between median OS and median iPFS persisted in the subgroups of different phases of trials and different types of lung cancer, ICI, and treatment modalities ($R_{WLS}^2$ ranging from 0.86 to 0.96), suggesting that the correlation between median OS and median iPFS might not be influenced by differences in phase of trials and types of lung cancer, ICI, and treatment modalities. Furthermore, a surrogate endpoint for OS would be more useful in phase 3 trials than phase 1 or 2 trials, because it usually takes a much longer time to follow-up in phase 3 trials.

This research also has other limitations. First, although an appropriate surrogate endpoint should be validated at both trial level and individual-patient-data level, we did not incorporate individual-patient-data due to the lack of corresponding data. For the design of trials for ICIIs in the future, the adoption of immune-related response evaluation criteria should be considered, and the surrogacy of iPFS should be further validated at individual-patient-data level in the future studies. Second, the update in iRECIST has overcome many disadvantages of previous criteria including irRC and irRECIST, but no data on trials assessed per iRECIST are available. Thus, whether the update in iRECIST could improve the correlation between OS and PFS compared with irRC or IrRECIST requires further study.

In conclusion, this systematic review and meta-analysis demonstrates a strong trial-level correlation between treatment effect (HR) on OS and iPFS. Similarly, a strong and robust trial-level correlation between median OS and iPFS across different phases of trials and different types of lung cancer, ICI, and treatment modalities in trials of ICIs in lung cancer were also presented. It suggests that iPFS provides valid and robust surrogacy for OS in trials of ICIs in lung cancer. Conversely, the moderate correlation between OS and cPFS provides only modest support for adopting cPFS as surrogate endpoint for OS in trials of ICIs in lung cancer. The conclusion should be further validated at the individual-patient-data level and phase 3 trials.

CONFLICTS OF INTEREST
The authors declare that there is no conflict of interest.

ETHICAL STATEMENT
Ethics approval was not required for this study.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Pubmed at https://pubmed.ncbi.nlm.nih.gov/, Embase at https://www.embase.com/, and Cochrane library at https://www.cochranelibrary.com.
REFERENCES

4. Foster NR, Renfro LA, Schild SE, et al. Multitrial evaluation of checkpoint inhibitors in patients with advanced non– small cell lung cancer (NSCLC): a systematic literature review. Oncoimmunology. 2020;9:1774314.

5. Foster NR, Qi Y, Shi Q, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011;117:1262-1271.

6. Zhao S, Zhang Z, Zhang Y, et al. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2015;10:1099-1106.

7. Laporte S, Squifflet P, Baroux N, et al. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. BMJ Open. 2013;3:e001802.

8. Mauguen A, Pignon J-P, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013;14:619-626.

9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.

10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-214.

11. Eisenhauer EA, Therasse P, Bogar J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.

12. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.

13. Chiofu VL, Buratto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541-3543.

14. Queirolo P, Spegano F. Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review. Cancer Treat Rev. 2017;59:71-78.

15. Bohnsack O, Hoos A, Ludacijk J. Adaptation of the immune-related response criteria: irRECIST. Ann Oncol. 2014;25:iv361-iv372.

16. Seymour L, Bogaerts J, Perrone A, et al. irRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-e152.

17. Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38(14):1505-1517.

18. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.

19. Ott P, Felip E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small cell lung cancer: updated survival results from KEYNOTE-028. J Thorac Oncol. 2017;12:3823-3829.

20. Nishio M, Takahashi T, Yoshioka H, et al. KEYNOTE-025: phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Cancer Sci. 2019;110:1012-1020.

21. Gubens MA, Sequist LV, Stevenson JP, et al. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer. 2019;130:59-66.

22. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.

23. Leigl NB, Hellmann MD, Hui R, et al. Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med. 2019;7:347-357.

24. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387-401.

25. Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (Atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29:vii743-vii744.

26. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous non-small-cell lung cancer (IMpower163): results from a randomized phase III trial. J Thorac Oncol. 2020;15:1351-1360.

27. National Library of Medicine (U.S.). (30 September 2015 – 1 October 2018). An investigational immuno-therapy study of nivolumab, or nivolumab in combination with ipilimumab, or placebo in patients with extensive-stage disease small cell lung cancer (ED-SCLC) after completion of platinum-based chemotherapy. Identifier NCT02538666. https://clinicaltrials.gov/show/NCT02538666. Accessed July 1, 2020.

28. National Library of Medicine (U.S.). (28 August 2015 – 17 August 2018). Effectiveness study of nivolumab compared to chemotherapy in patients with relapsed small-cell lung cancer. Identifier NCT02481830. https://clinicaltrials.gov/show/NCT02481830. Accessed July 1, 2020.

29. Peters S, Ramalingam SS, Paz-Ares L, et al. Nivolumab + low-dose ipilimumab vs platinum-doublet chemotherapy as first-line
30. National Library of Medicine (U.S.). (10 December 2015 – 15 September 2017). Efficacy study of nivolumab compared to docetaxel in subjects previously treated with advanced or metastatic non small cell lung cancer. Identifier NCT02613507. https://clinicaltrials.gov/show/NCT02613507. Accessed July 1, 2020.

31. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883-895.

32. Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415-2426.

33. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35:3924-3933.

34. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33:2004-2012.

35. Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35:2781-2789.

36. Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small-cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6:661-674.

37. Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020;31:609-618.

38. Wrangle JM, Velcheti V, Patel MR, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19:694-704.

39. National Library of Medicine (U.S.). (13 December 2011 – 19 November 2015). Trial in extensive- disease small cell lung cancer: two randomization studies comparing docetaxel with or without ipilimumab (an Engineered Anti-PD1 Antibody) compared with ipilimumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276-1282.

40. Theelen WSME, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer. J Clin Oncol. 2017;35:3449-3457.

41. National Library of Medicine (U.S.). (13 December 2011 – 19 March 2015). Trial in extensive-disease small cell lung cancer (ED-SCLC) subjects comparing ipilimumab plus etoposide and platinum therapy to etoposide and platinum therapy alone. Identifier NCT01450761. https://clinicaltrials.gov/show/NCT01450761. Accessed July 1, 2020.

42. National Library of Medicine (U.S.). (6 August 2013 – 19 November 2015). A randomized phase 2 study of atezolizumab (an Engineered Anti-PDL1 Antibody) compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy—“POPLAR”. Identifier NCT01903993. https://clinicaltrials.gov/show/NCT01903993. Accessed July 1, 2020.

43. Goldman JW, Waterhouse DM, George B, et al. Safety and efficacy results of a phase I, open-label study of concurrent and delayed nivolumab in combination with nab-paclitaxel and carboplatin in advanced non-small cell lung cancer. Front Oncol. 2019;9:1256.

44. Bazhenova L, Redman M, Gettinger S, et al. OA04.01 A phase III randomized study of nivolumab/ipilimumab vs nivolumab for previously treated stage IV squamous cell lung cancer. J Thorac Oncol. 2019;14:S214.

45. Cho BC, Yoh K, Bar J, et al. Results from a phase I study of MK-1308 (anti-CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer. Ann Oncol. 2019;30:xii36-xii37.

46. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040-2051.
advanced non-small cell lung cancer: a phase II study. *Ann Oncol*. 2018;29:viii531.

57. Lee JS, Lee KH, Cho EK, et al. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. *Lung Cancer*. 2018;122:234-242.

58. Liu SV, Camidge DR, Gettinger SN, et al. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. *Eur J Cancer*. 2018;101:114-122.

59. Socinski M, Velcheti V, Mekhail T, et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden as a predictive biomarker for atezolizumab in 1L non-small cell lung cancer. *Ann Oncol*. 2019;30:v919-v920.

60. Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. *Cancer Sci*. 2017;108:1000-1006.

61. Sequist LV, Chiang A, Gilbert J, et al. Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab trial in extensive-stage small cell lung cancer. *Ann Oncol*. 2016;27:v493.

62. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. *Lancet Oncol*. 2017;18:e95-903.

63. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. *J Clin Oncol*. 2012;30:2046-2054.

64. Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. *Ann Oncol*. 2013;24:75-83.

65. Arriola E, Wheater M, Galea I, et al. Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC. *J Thorac Oncol*. 2016;11:1511-1521.

66. Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). *J Clin Oncol*. 2018;36:1393-1399.

67. Mattes MD, Eubank TD, Almubarak M, et al. Outcomes from a phase II clinical trial evaluating the systemic (abscopal) response from the addition of local radiation to standard-of-care immunotherapy for metastatic non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2019;105:E519.

68. Chiang AC, Sequist LVD, Gilbert J, et al. Clinical activity and safety of atezolizumab in a phase 1 study of patients with relapsed/refractory small-cell lung cancer. *Clin Lung Cancer*. 2020;21:455-463.

69. Mulkey F, Theoret MR, Keegan P, Pazdur R, Sridhara R. Comparison of iRECIST versus RECIST v1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. *J Immunother Cancer*. 2020;8:e000146.

70. Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. *Am Soc Clin Oncol Educ Book*. 2018;38:169-178.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Zhu G-L, Yang K-B, Tang S-Q, Peng L. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. *Cancer Med*. 2021;10:8272-8287. doi:10.1002/cam4.4347